Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352509 | 0.94 | OPRL1 (0.39) | OPRL1OPRM1TRPA1HSD11B1PGR | |
| SCHEMBL2030849 | 0.94 | OPRL1 (0.38) | OPRL1OPRM1TRPA1HSD11B1PGR | |
| SCHEMBL513971 | 0.86 | HSD11B1 (0.36) | OPRL1OPRM1TRPA1HSD11B1PGR | |
| SCHEMBL513972 | 0.86 | HSD11B1 (0.36) | OPRL1OPRM1TRPA1HSD11B1PGR | |
| SCHEMBL1351916 | 0.83 | PGR (0.37) | OPRL1OPRM1TRPA1HSD11B1PGR | |
| SCHEMBL17510774 | 0.81 | OPRM1 (0.53) | OPRL1OPRM1 | |
| SCHEMBL2696940 | 0.80 | OPRM1 (0.42) | OPRL1OPRM1MEN1KMT2A | |
| SCHEMBL1900125 | 0.80 | CTSL (0.32) | OPRL1OPRM1CYP2C9 | |
| SCHEMBL2028947 | 0.79 | GRM5 (0.37) | OPRL1OPRM1 | |
| SCHEMBL2032267 | 0.75 | OPRM1 (0.37) | OPRL1OPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011123678-A2 | SUBSTITUTED BENZO-PYRIDO-TRIAZOLO-DIAZEPINE COMPOUNDS | ARQULE, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245236-A1 | Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245236-A1 | Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds | BRD4, PDXK, THPO | OPRL1 2337/4885OPRM1 3584/4885TRPA1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.